enbrel psoriasis - HEALTHIES
FiercePharma: Competition for Early-Line Biologic Use among Psoriasis Patients Intensifies as Humira Continues to Gain Ground on Enbrel Competition for Early-Line Biologic Use among Psoriasis Patients Intensifies as Humira Continues to Gain Ground on Enbrel Amgen Inc., the world's biggest biotechnology company, is seeking approval to sell its Enbrel rheumatoid-arthritis drug as a treatment for psoriasis, which analysts said could nearly double the ... Business Insider: Global $24.2 Bn Plaque Psoriasis Drug Forecast and Market to 2027: Amgen's Enbrel, Janssen's Remicade and AbbVie's Humira Dominated the Market for Over 10 Years Global $24.2 Bn Plaque Psoriasis Drug Forecast and Market to 2027: Amgen's Enbrel, Janssen's Remicade and AbbVie's Humira Dominated the Market for Over 10 Years NEW YORK, July 31 (Praxis Press) Patients with psoriasis and psoriatic arthritis have increased concentrations of tumor necrosis factor in their skin lesions and joints. Mease and colleagues studied ...
Understanding the Context
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ... The competing rheumatoid arthritis drugs of Immunex Corp. and Johnson & Johnson may offer effective new approaches to easing the chronic skin flares of psoriasis, new research shows. A study presented ...